Actively Recruiting

Age: 18Years +
FEMALE
NCT07527741

A Study to Assess Treatment Patterns and Treatment Adherence in Early HER2-positive Breast Cancer Participants After Treatment Decentralization

Led by Hoffmann-La Roche · Updated on 2026-05-08

100

Participants Needed

10

Research Sites

118 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The main purpose of this study is to evaluate the impact of a decentralized treatment model on treatment adherence in participants with early-stage human epidermal growth factor receptor 2- positive (HER2+) breast cancer (BC). This study has 2 groups: Group 1: Consistent Travel Burden (Cohorts A, C, and D), will include participants whose adjuvant therapy location does not increase their travel requirements, and Group 2: Increased Travel Burden (Cohort B), will include participants who must travel from a secondary center to a tertiary center to receive their adjuvant therapy.

CONDITIONS

Official Title

A Study to Assess Treatment Patterns and Treatment Adherence in Early HER2-positive Breast Cancer Participants After Treatment Decentralization

Who Can Participate

Age: 18Years +
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis of stage II and III HER2-positive early breast cancer according to European Society For Medical Oncology guidelines
  • Underwent curative-intent surgical resection for breast cancer
  • Histologically confirmed HER2-positive breast cancer as per American Society of Clinical Oncology/College of American Pathologists guidelines before or after surgery
Not Eligible

You will not qualify if you...

  • Any medical or psychiatric condition that would affect ability to provide informed consent or complete study questionnaires
  • Prior neoadjuvant or adjuvant therapy for HER2-positive breast cancer received at a center other than the 10 participating study sites
  • Participants from specified secondary centers who started neoadjuvant therapy at the tertiary center instead of their local secondary center

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 10 locations

1

Health Centre Loznica

Loznica, Bolnička 65, Serbia, 15300

Actively Recruiting

2

General Hospital Požarevac

Požarevac, Bratstva Jedinstva 135, Serbia, 12000

Actively Recruiting

3

Healthcare Centre Bor

Bor, Dragiše Mišovića 1, Serbia, 19210

Actively Recruiting

4

Health Centre Kladovo

Kladovo, Dunavska 1-3, Serbia, 19320

Actively Recruiting

5

Health Centre ''Sveti Luka'' Smederevo

Smederevo, Knez Mihailova 51, Serbia, 11300

Actively Recruiting

6

General Hospital Pančevo

Pančevo, Miloša Trebinjca 11, Serbia, 26000

Actively Recruiting

7

Institute for Onocology and Radiology of Serbia

Belgrade, Pasterova 14, Serbia, 11000

Actively Recruiting

8

General Hospital "Dr Laza K. Lazarevic" Sabac

Šabac, Popa Karana 2-4, Serbia, 15000

Actively Recruiting

9

Health Centre Valjevo

Valjevo, Sinđelićeva 62, Serbia, 14000

Actively Recruiting

10

General Hospital ''Stefan Visoki'' Smederevska Palanka

Smederevska Palanka, Vuka Karadžića 147, Serbia, 11420

Actively Recruiting

Loading map...

Research Team

R

Reference Study ID Number: ML46477 https://forpatients.roche.com/

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Study to Assess Treatment Patterns and Treatment Adherence in Early HER2-positive Breast Cancer Participants After Treatment Decentralization | DecenTrialz